MAP2K7 and melanoma: Recently Hass et al69 demonstrated that the acquisition of resistance to targeted anti-MAPK therapy (with MEK or RAF inhibitors) conferred cross-resistance to immunotherapy in melanoma and they proposed that immunotherapy should be administrated before patients develop resistance to anti-MEK1/2.